Published in
American Society of Hematology, Blood, 12(125), p. 1976-1985, 2015
DOI: 10.1182/blood-2014-09-599910
Links
- American Society of Hematology | PDF
- [europepmc.org] | PDF
- [epublications.marquette.edu] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar
Journal article published in 2015 by
Omozuanvbo Aisiku,
Christian G. Peters,
Karen De Ceunynck,
Chandra C. Ghosh,
James R. Dilks,
Susanna F. Fustolo Gunnink,
Mingdong Huang,
Chris Dockendorff,
Samir M. Parikh,
Robert Flaumenhaft
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Parmodulins are a new class of PAR1 inhibitors that target the cytosolic face of PAR1 to block signaling through Gαq, but not Gα12/13. Unlike vorapaxar, which causes endothelial injury, parmodulins selectively block proinflammatory, but not cytoprotective, signaling.